{
    "nctId": "NCT04418089",
    "briefTitle": "Simvastatin Effect in Combination With Neoadjuvant Chemotherapy to Clinical Response and Tumor-Free Margin in Locally Advanced Breast Cancer",
    "officialTitle": "Combination of CAF and Simvastatin Improves Response to Neoadjuvant Chemotherapy and Increases Tumor-Free Margin in Locally Advanced Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Chemotherapy Effect",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Clinical Response as WHO 1979",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* LABC IIIA-IIIC TNM / AJCC 2018 with histopathological examination.\n* Patients are planned to get NACT\n* Performance status of Eastern Cooperative Oncology Group (ECOG) 0-2.\n* LABC patients who have not received surgery, radiation or systemic therapy and previous statin therapy.\n* Normal kidney organ function (serum creatinine \u2264 1.5 upper limit normal).\n* Normal liver organ function (ALT \u2264 2 times the normal limit, or total bilirubin level \u2264 1.5 times the normal upper limit)\n* Heart function (E / F)\\> 55%\n* Willing to participate in this study by signing an informed consent\n\nExclusion Criteria:\n\n* LABC patients are both residual and recurrent.\n* Allergy to tattoo ink\n* Allergy to statins\n* Patients are pregnant or breastfeeding",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}